Iambic Therapeutics, Inc. (IAM) company profile
IAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$13.10−1.74 (-11.73%)
Close on Nov 13, 2026Market cap –P/E –Yield –
About Iambic Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Iambic Therapeutics, Inc. is listed on Nasdaq under the ticker IAM, in the SEC industry Biological Products, (No Diagnostic Substances). It is incorporated in Delaware and its fiscal year ends on December 31.
Company profile
Company
- Legal name
- Iambic Therapeutics, Inc.
- Headquarters
- San Diego, CA
- Address
- 5627 Oberlin Drive, Suite 120 92121
- Phone
- (626) 592-2520
- Website
- iambic.ai
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- IAM
- Exchange
- Nasdaq
- IPO date
- Oct 15, 2026
- SEC CIK
- 1997038
- CUSIP
- 45076A101
- ISIN
- US45076A1016
- FIGI
- BBG011RJ5Z57
- Share class FIGI
- BBG011RJ5Z66
- EIN
- 84-3364168
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Frederick R. Manby | Chief Technology Officer, Director | 1,862,665 |
| Thomas F. Miller | Chief Executive Officer, Director | 1,410,756 |
| Michael Secora | CFO & Chief Corp Dev Ofcr | 279,902 |
| Peter A. Olson | Chief Scientific Officer | 30,909 |
| Neil Josephson | Chief Medical Officer | 71,459 |
| William H. Rastetter | Director | 200,920 |
| R. Jacob Vogelstein | Director | 742,546 |
| Evan Lockwood Rachlin | Director | 57,754 |
| Kurt Von Emster | Director | – |
| Shalini Sharp | Director | – |
| Mary Tagliaferri | Director | – |
| Samit Hirawat | Director | – |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 15, 2026
- Offer price
- $16.00
- Securities offered
- 9,375,000
- Gross proceeds
- $150.00M
- Exchange
- Nasdaq
- First trading day
- Oct 15, 2026
- First-day close
- $18.91+18.2%
- Lock-up ends (est.)
- Apr 13, 2027
“The initial public offering price is $16.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 15, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 13, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?